InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,105.06
(
1.12%
)
US TECH 100
17,252.40
(
1.62%
)
Dow Jones
38,279.99
(
0.51%
)
Brent Oil
88.17
(
0.02%
)
Bitcoin
64,126.94
(
-0.55%
)
Post# of 251616
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119493
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Titan V post# 210929

Thursday, 04/27/2017 3:58:14 PM

Thursday, April 27, 2017 3:58:14 PM

Post# of 251616

Exact Sciences is also acquiring MDxHealth patents directed toward colorectal cancer, including its DNA methylation biomarker, NDRG4, as well as technology covering the use of FIT (fecal immunochemical test) in combination with methylation. These acquisitions include one-time fees totaling $15 million, including payments accrued since July 2016.

This presumably obviates the need for EXAS to MDxHealth a royalty on Cologuard sales.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up